Few molecules in biochemistry have enjoyed such a long and storied research history as nicotinamide adenine dinucleotide — better known as NAD+. First identified over a century ago, this small but mighty coenzyme has proven itself indispensable to virtually every form of life on Earth. It sits at the crossroads of energy metabolism, DNA repair, gene expression, and cellular signalling, making it one of the most studied molecules in modern biology.
Yet despite more than a hundred years of investigation, NAD+ continues to surprise researchers. New roles for this coenzyme are still being uncovered, and it has become a focal point for some of the most exciting areas of contemporary biological research — from ageing and neurodegeneration to circadian biology and mitochondrial dysfunction.
In this article, we trace the history of NAD+ research, explore its core biology, and examine why this coenzyme remains at the frontier of scientific inquiry.
A Brief History: From Fermentation to the Forefront
The story of NAD+ begins in 1906, when British biochemists Arthur Harden and William John Young were studying alcoholic fermentation in yeast extracts. They observed that boiling the extract destroyed its ability to ferment sugar — but adding back the boiled, filtered liquid restored activity. Something heat-stable and of low molecular weight was clearly essential to the process. They called it “cozymase.” It would take decades before this mysterious factor was fully characterised, but Harden and Young had stumbled upon what we now know as NAD+.
Through the 1930s and 1940s, the work of Otto Warburg, Hans von Euler-Chelpin, and Arthur Kornberg progressively elucidated the chemical structure and enzymatic roles of NAD+. Warburg demonstrated its function as a hydrogen carrier in redox reactions — a discovery so fundamental that it reshaped our understanding of how cells generate energy. Von Euler-Chelpin received the Nobel Prize in Chemistry in 1929 in part for his work on coenzymes in fermentation, and Kornberg’s early career included pivotal studies on NAD+ biosynthesis before he went on to his Nobel-winning work on DNA replication.
For much of the twentieth century, NAD+ was understood primarily as a metabolic workhorse — a cofactor shuttling electrons in core energy pathways. That understanding was accurate, but it was incomplete. The late 1990s and early 2000s would bring a dramatic expansion of the NAD+ story, revealing it as a critical signalling molecule with far-reaching biological consequences.
Core Biology: The Engine Room of Cellular Metabolism
At its most fundamental level, NAD+ is a coenzyme found in every living cell. It exists in two forms: the oxidised form (NAD+) and the reduced form (NADH). The interconversion between these two states is central to cellular energy metabolism.
Redox Reactions and Electron Transfer
NAD+ accepts electrons and a hydrogen atom from metabolic substrates, becoming NADH in the process. This redox cycling is essential for three of the most important energy-producing pathways in the cell:
Glycolysis. In the cytoplasm, glucose is broken down into pyruvate. During this process, NAD+ is reduced to NADH at the glyceraldehyde-3-phosphate dehydrogenase step, capturing energy that will be used downstream.
The TCA cycle (Krebs cycle). Inside the mitochondrial matrix, acetyl-CoA is oxidised through a series of reactions. Three steps in the TCA cycle generate NADH from NAD+, feeding electrons into the electron transport chain.
Oxidative phosphorylation. NADH donates its electrons to Complex I of the electron transport chain in the inner mitochondrial membrane. This initiates a cascade of electron transfers that ultimately drives ATP synthase to produce ATP — the cell’s primary energy currency. In the process, NADH is re-oxidised to NAD+, completing the cycle.
Without adequate NAD+, these pathways grind to a halt. The ratio of NAD+ to NADH is therefore a critical indicator of cellular metabolic health, and perturbations in this ratio have been observed in numerous disease models studied in laboratory settings.
Beyond Energy: A Consumed Substrate
What distinguishes NAD+ from many other cofactors is that it is not merely borrowed and returned by enzymes — it is actively consumed in several important reactions. This means the cell must continuously synthesise and recycle NAD+ to maintain adequate pools. This distinction has profound implications for research, as it means NAD+ availability can become rate-limiting for critical cellular processes.
NAD+ as a Signalling Molecule: Sirtuins, PARPs, and CD38
The modern renaissance of NAD+ research was ignited by a series of discoveries linking NAD+ to cellular signalling pathways with deep connections to ageing, stress responses, and genome maintenance.
Sirtuins
Perhaps the most significant breakthrough came with the characterisation of sirtuins — a family of NAD+-dependent deacetylase and ADP-ribosyltransferase enzymes. In mammals, seven sirtuins (SIRT1–SIRT7) have been identified, each localised to different cellular compartments and each with distinct substrates and functions.
The pioneering work of Leonard Guarente at MIT and David Sinclair at Harvard brought sirtuins into the spotlight. Guarente’s laboratory demonstrated that Sir2 (the yeast sirtuin) extended lifespan in model organisms when overexpressed, and that its activity was directly dependent on NAD+ availability. Sinclair’s research group subsequently showed that NAD+ precursors could activate sirtuin pathways in aged animal models, with observed effects on mitochondrial function, inflammation markers, and metabolic parameters.
Crucially, sirtuins consume NAD+ as a co-substrate — they cleave NAD+ to produce nicotinamide (NAM) and O-acetyl-ADP-ribose as part of their catalytic mechanism. This means sirtuin activity is directly tied to the cellular NAD+ pool. When NAD+ levels fall, sirtuin activity diminishes — with potentially broad consequences for gene regulation, mitochondrial biogenesis, and stress resistance.
PARPs (Poly ADP-Ribose Polymerases)
PARPs are another major family of NAD+-consuming enzymes. PARP1, the best-characterised member, plays a central role in DNA damage detection and repair. When PARP1 detects a single-strand DNA break, it uses NAD+ to synthesise poly ADP-ribose (PAR) chains, which serve as a scaffold for recruiting repair machinery.
Under conditions of mild DNA damage, PARP activity is a vital guardian of genomic integrity. However, under conditions of severe or chronic damage, PARP1 can consume NAD+ at a prodigious rate — potentially depleting cellular pools and triggering metabolic crisis. This dynamic has been extensively studied in cell culture and animal models of ischaemia, neurodegeneration, and inflammatory conditions.
CD38
CD38 is a transmembrane glycoprotein and one of the primary NAD+-degrading enzymes in mammalian tissues. Research has shown that CD38 expression increases with age in multiple tissue types in animal models, and this increase correlates with declining NAD+ levels. Pharmacological inhibition of CD38 in murine models has been shown to restore NAD+ levels and improve several metabolic parameters — findings that have generated considerable interest in the research community.
The interplay between sirtuins, PARPs, and CD38 creates a dynamic competition for the available NAD+ pool. Understanding how this competition is regulated — and how it shifts under various experimental conditions — remains an active and productive area of investigation.
The NAD+ Decline: What Research Models Show
One of the most consistent findings across NAD+ research is that NAD+ levels decline with age. This has been demonstrated in multiple tissue types and across several model organisms, from yeast and worms to mice.
In murine models, tissue NAD+ levels have been shown to decrease by as much as 50% between young adulthood and old age. This decline has been associated in research settings with:
Reduced mitochondrial function and impaired oxidative phosphorylation
Accumulation of DNA damage and reduced PARP-mediated repair capacity
Diminished sirtuin activity and altered gene expression profiles
Increased inflammatory signalling (sometimes referred to as “inflammageing” in the literature)
Disrupted circadian rhythm regulation
The mechanisms driving this decline appear to be multifactorial. Increased CD38 activity, chronic low-grade PARP activation in response to accumulated DNA damage, and reduced activity of NAD+ biosynthetic enzymes have all been implicated. Disentangling these contributing factors remains a significant challenge — and opportunity — for researchers in the field.
Key Research Areas
DNA Repair and Genomic Stability
NAD+’s role as a PARP substrate places it at the centre of DNA repair research. Studies in cell culture have demonstrated that NAD+ depletion impairs the repair of single-strand breaks, leading to their conversion into more dangerous double-strand breaks. Animal models with boosted NAD+ levels have shown improved DNA repair capacity and reduced markers of genomic instability.
Mitochondrial Function
Sirtuins — particularly SIRT1 and SIRT3 — are key regulators of mitochondrial biogenesis and function. Research in aged murine models has shown that restoring NAD+ levels can reactivate SIRT1-mediated deacetylation of PGC-1-alpha, a master regulator of mitochondrial biogenesis, leading to measurable improvements in mitochondrial membrane potential and respiratory capacity.
Circadian Rhythm Regulation
NAD+ levels oscillate in a circadian pattern, and the NAD+-dependent sirtuin SIRT1 has been shown to interact directly with core clock machinery, including CLOCK and BMAL1. Research in animal models has demonstrated that disrupting NAD+ metabolism can desynchronise circadian gene expression — and, conversely, that supporting NAD+ availability can help restore circadian function in aged models.
Neurodegeneration Models
NAD+ depletion has been observed in animal models of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Supplementation with NAD+ precursors in these models has shown effects on neuronal survival, synaptic plasticity, and neuroinflammatory markers. SIRT3-mediated mitochondrial protection and PARP-mediated DNA repair both appear to play roles in these contexts, though the precise mechanisms are still being elucidated.
NAD+ Precursors vs. Direct NAD+ in Research
Researchers investigating NAD+ biology have several tools at their disposal when it comes to modulating NAD+ levels in experimental systems.
Precursor Approaches
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the two most widely studied NAD+ precursors. Both enter the salvage pathway and are enzymatically converted to NAD+ within cells. NMN is one step closer to NAD+ in the biosynthetic pathway, requiring only the enzyme NMNAT for conversion, while NR must first be phosphorylated by nicotinamide riboside kinases (NRKs) to form NMN.
Both precursors have been extensively used in animal studies, where they have been shown to elevate tissue NAD+ levels and activate downstream sirtuin pathways. However, the pharmacokinetics, tissue distribution, and dose-response relationships of these precursors differ — variables that researchers must carefully consider when designing experiments.
Direct NAD+ in Research
Direct NAD+ is also used in laboratory research, particularly in cell culture and in vitro enzymatic assays where precise control over NAD+ concentrations is required. In cell-free systems, direct NAD+ allows researchers to study sirtuin kinetics, PARP activity, and other NAD+-dependent reactions without the confounding variable of biosynthetic conversion.
The choice between precursors and direct NAD+ depends on the experimental question. For in vivo studies exploring systemic NAD+ metabolism, precursors are often preferred due to their bioavailability profiles. For mechanistic in vitro work, direct NAD+ provides the precision needed to dissect enzyme kinetics and pathway dynamics.
The NAD+ Metabolome: Salvage and De Novo Synthesis
NAD+ is not simply consumed and discarded — it is recycled through elegant biosynthetic pathways that the cell tightly regulates.
The Salvage Pathway
The salvage pathway is the dominant route for maintaining NAD+ levels in most mammalian cell types. When NAD+ is consumed by sirtuins, PARPs, or CD38, it releases nicotinamide (NAM) as a byproduct. The enzyme nicotinamide phosphoribosyltransferase (NAMPT) — often described as the rate-limiting enzyme in NAD+ salvage — converts NAM to NMN. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).
NAMPT expression and activity have themselves become subjects of intense research. NAMPT levels fluctuate with circadian rhythm and decline with age in several tissue types in animal models, potentially contributing to the age-related drop in NAD+.
De Novo Synthesis
NAD+ can also be synthesised de novo from the amino acid tryptophan via the kynurenine pathway. This route is particularly important in liver and kidney tissue. The de novo pathway involves multiple enzymatic steps and is regulated at several points, most notably at indoleamine 2,3-dioxygenase (IDO) and quinolinate phosphoribosyltransferase (QPRT).
Understanding the relative contributions of salvage versus de novo synthesis in different tissues and under different experimental conditions is an ongoing area of research, with implications for how NAD+ depletion is best addressed in various model systems.
Current State of Research and Future Directions
NAD+ research is entering what many scientists consider a golden era. Several key questions are driving the field forward:
Tissue-specific NAD+ dynamics. How do NAD+ levels, consumption rates, and biosynthetic capacity differ across tissues? Emerging metabolomic and isotope-tracing techniques are beginning to provide answers.
NAD+ compartmentalisation. NAD+ pools in the cytoplasm, mitochondria, and nucleus appear to be regulated semi-independently. Understanding how these compartments communicate — and how perturbations in one affect the others — is a frontier of current research.
The NAD+/inflammation axis. The relationship between NAD+ metabolism and inflammatory signalling is complex and bidirectional. CD38 upregulation by inflammatory cytokines, and the anti-inflammatory effects of sirtuin activation, suggest that NAD+ sits at a critical node in the immunometabolic network.
Combination approaches. Researchers are increasingly exploring how NAD+ modulation interacts with other interventions in model systems — including caloric restriction mimetics, senolytic compounds, and mitochondrial-targeted antioxidants.
Improved analytical tools. Biosensors capable of measuring NAD+ in real time within living cells are being refined, promising to reveal dynamic fluctuations that traditional bulk measurements cannot capture.
The breadth of NAD+’s involvement in cellular biology means that advances in NAD+ research are likely to ripple outward across many fields, from basic cell biology to models of age-related decline, metabolic dysfunction, and neurodegeneration.
Handling and Storage Notes for Researchers
NAD+ is a relatively fragile molecule that requires careful handling in the laboratory:
Storage. NAD+ should be stored desiccated at -20 degrees C or below. Repeated freeze-thaw cycles should be avoided, as they can accelerate degradation.
Solution preparation. Aqueous solutions of NAD+ should be prepared fresh when possible. If storage of solutions is necessary, aliquot and freeze at -80 degrees C to minimise hydrolysis.
pH sensitivity. NAD+ is most stable in mildly acidic to neutral pH ranges. Strongly alkaline conditions accelerate decomposition.
Light sensitivity. Protect NAD+ solutions from prolonged exposure to direct light, which can promote photodegradation.
Researchers should consult the certificate of analysis provided with their specific product for purity data and any batch-specific storage recommendations.
Conclusion
From its accidental discovery in a yeast fermentation experiment in 1906 to its current position at the cutting edge of ageing and metabolic research, NAD+ has proven to be one of the most consequential molecules in biochemistry. Its dual roles as a metabolic cofactor and a consumed signalling substrate give it a unique position in cellular biology — one that researchers are still working to fully understand.
As analytical tools improve and our understanding of NAD+ compartmentalisation, tissue-specific dynamics, and cross-pathway interactions deepens, this century-old molecule continues to open new doors for scientific investigation. For researchers working in metabolism, ageing biology, DNA repair, and beyond, NAD+ remains an indispensable subject of study — and a remarkably productive one.
This material is provided by Trusted Peptides for informational and research purposes only. NAD+ products supplied by Trusted Peptides are intended solely for in vitro and in vivo laboratory research. They are not intended for human consumption, therapeutic use, or diagnostic purposes. Researchers are responsible for ensuring compliance with all applicable regulations and institutional guidelines.
NAD+: A Century of Research and Why This Coenzyme Still Captivates Scientists
Few molecules in biochemistry have enjoyed such a long and storied research history as nicotinamide adenine dinucleotide — better known as NAD+. First identified over a century ago, this small but mighty coenzyme has proven itself indispensable to virtually every form of life on Earth. It sits at the crossroads of energy metabolism, DNA repair, gene expression, and cellular signalling, making it one of the most studied molecules in modern biology.
Yet despite more than a hundred years of investigation, NAD+ continues to surprise researchers. New roles for this coenzyme are still being uncovered, and it has become a focal point for some of the most exciting areas of contemporary biological research — from ageing and neurodegeneration to circadian biology and mitochondrial dysfunction.
In this article, we trace the history of NAD+ research, explore its core biology, and examine why this coenzyme remains at the frontier of scientific inquiry.
A Brief History: From Fermentation to the Forefront
The story of NAD+ begins in 1906, when British biochemists Arthur Harden and William John Young were studying alcoholic fermentation in yeast extracts. They observed that boiling the extract destroyed its ability to ferment sugar — but adding back the boiled, filtered liquid restored activity. Something heat-stable and of low molecular weight was clearly essential to the process. They called it “cozymase.” It would take decades before this mysterious factor was fully characterised, but Harden and Young had stumbled upon what we now know as NAD+.
Through the 1930s and 1940s, the work of Otto Warburg, Hans von Euler-Chelpin, and Arthur Kornberg progressively elucidated the chemical structure and enzymatic roles of NAD+. Warburg demonstrated its function as a hydrogen carrier in redox reactions — a discovery so fundamental that it reshaped our understanding of how cells generate energy. Von Euler-Chelpin received the Nobel Prize in Chemistry in 1929 in part for his work on coenzymes in fermentation, and Kornberg’s early career included pivotal studies on NAD+ biosynthesis before he went on to his Nobel-winning work on DNA replication.
For much of the twentieth century, NAD+ was understood primarily as a metabolic workhorse — a cofactor shuttling electrons in core energy pathways. That understanding was accurate, but it was incomplete. The late 1990s and early 2000s would bring a dramatic expansion of the NAD+ story, revealing it as a critical signalling molecule with far-reaching biological consequences.
Core Biology: The Engine Room of Cellular Metabolism
At its most fundamental level, NAD+ is a coenzyme found in every living cell. It exists in two forms: the oxidised form (NAD+) and the reduced form (NADH). The interconversion between these two states is central to cellular energy metabolism.
Redox Reactions and Electron Transfer
NAD+ accepts electrons and a hydrogen atom from metabolic substrates, becoming NADH in the process. This redox cycling is essential for three of the most important energy-producing pathways in the cell:
Without adequate NAD+, these pathways grind to a halt. The ratio of NAD+ to NADH is therefore a critical indicator of cellular metabolic health, and perturbations in this ratio have been observed in numerous disease models studied in laboratory settings.
Beyond Energy: A Consumed Substrate
What distinguishes NAD+ from many other cofactors is that it is not merely borrowed and returned by enzymes — it is actively consumed in several important reactions. This means the cell must continuously synthesise and recycle NAD+ to maintain adequate pools. This distinction has profound implications for research, as it means NAD+ availability can become rate-limiting for critical cellular processes.
NAD+ as a Signalling Molecule: Sirtuins, PARPs, and CD38
The modern renaissance of NAD+ research was ignited by a series of discoveries linking NAD+ to cellular signalling pathways with deep connections to ageing, stress responses, and genome maintenance.
Sirtuins
Perhaps the most significant breakthrough came with the characterisation of sirtuins — a family of NAD+-dependent deacetylase and ADP-ribosyltransferase enzymes. In mammals, seven sirtuins (SIRT1–SIRT7) have been identified, each localised to different cellular compartments and each with distinct substrates and functions.
The pioneering work of Leonard Guarente at MIT and David Sinclair at Harvard brought sirtuins into the spotlight. Guarente’s laboratory demonstrated that Sir2 (the yeast sirtuin) extended lifespan in model organisms when overexpressed, and that its activity was directly dependent on NAD+ availability. Sinclair’s research group subsequently showed that NAD+ precursors could activate sirtuin pathways in aged animal models, with observed effects on mitochondrial function, inflammation markers, and metabolic parameters.
Crucially, sirtuins consume NAD+ as a co-substrate — they cleave NAD+ to produce nicotinamide (NAM) and O-acetyl-ADP-ribose as part of their catalytic mechanism. This means sirtuin activity is directly tied to the cellular NAD+ pool. When NAD+ levels fall, sirtuin activity diminishes — with potentially broad consequences for gene regulation, mitochondrial biogenesis, and stress resistance.
PARPs (Poly ADP-Ribose Polymerases)
PARPs are another major family of NAD+-consuming enzymes. PARP1, the best-characterised member, plays a central role in DNA damage detection and repair. When PARP1 detects a single-strand DNA break, it uses NAD+ to synthesise poly ADP-ribose (PAR) chains, which serve as a scaffold for recruiting repair machinery.
Under conditions of mild DNA damage, PARP activity is a vital guardian of genomic integrity. However, under conditions of severe or chronic damage, PARP1 can consume NAD+ at a prodigious rate — potentially depleting cellular pools and triggering metabolic crisis. This dynamic has been extensively studied in cell culture and animal models of ischaemia, neurodegeneration, and inflammatory conditions.
CD38
CD38 is a transmembrane glycoprotein and one of the primary NAD+-degrading enzymes in mammalian tissues. Research has shown that CD38 expression increases with age in multiple tissue types in animal models, and this increase correlates with declining NAD+ levels. Pharmacological inhibition of CD38 in murine models has been shown to restore NAD+ levels and improve several metabolic parameters — findings that have generated considerable interest in the research community.
The interplay between sirtuins, PARPs, and CD38 creates a dynamic competition for the available NAD+ pool. Understanding how this competition is regulated — and how it shifts under various experimental conditions — remains an active and productive area of investigation.
The NAD+ Decline: What Research Models Show
One of the most consistent findings across NAD+ research is that NAD+ levels decline with age. This has been demonstrated in multiple tissue types and across several model organisms, from yeast and worms to mice.
In murine models, tissue NAD+ levels have been shown to decrease by as much as 50% between young adulthood and old age. This decline has been associated in research settings with:
The mechanisms driving this decline appear to be multifactorial. Increased CD38 activity, chronic low-grade PARP activation in response to accumulated DNA damage, and reduced activity of NAD+ biosynthetic enzymes have all been implicated. Disentangling these contributing factors remains a significant challenge — and opportunity — for researchers in the field.
Key Research Areas
DNA Repair and Genomic Stability
NAD+’s role as a PARP substrate places it at the centre of DNA repair research. Studies in cell culture have demonstrated that NAD+ depletion impairs the repair of single-strand breaks, leading to their conversion into more dangerous double-strand breaks. Animal models with boosted NAD+ levels have shown improved DNA repair capacity and reduced markers of genomic instability.
Mitochondrial Function
Sirtuins — particularly SIRT1 and SIRT3 — are key regulators of mitochondrial biogenesis and function. Research in aged murine models has shown that restoring NAD+ levels can reactivate SIRT1-mediated deacetylation of PGC-1-alpha, a master regulator of mitochondrial biogenesis, leading to measurable improvements in mitochondrial membrane potential and respiratory capacity.
Circadian Rhythm Regulation
NAD+ levels oscillate in a circadian pattern, and the NAD+-dependent sirtuin SIRT1 has been shown to interact directly with core clock machinery, including CLOCK and BMAL1. Research in animal models has demonstrated that disrupting NAD+ metabolism can desynchronise circadian gene expression — and, conversely, that supporting NAD+ availability can help restore circadian function in aged models.
Neurodegeneration Models
NAD+ depletion has been observed in animal models of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Supplementation with NAD+ precursors in these models has shown effects on neuronal survival, synaptic plasticity, and neuroinflammatory markers. SIRT3-mediated mitochondrial protection and PARP-mediated DNA repair both appear to play roles in these contexts, though the precise mechanisms are still being elucidated.
NAD+ Precursors vs. Direct NAD+ in Research
Researchers investigating NAD+ biology have several tools at their disposal when it comes to modulating NAD+ levels in experimental systems.
Precursor Approaches
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the two most widely studied NAD+ precursors. Both enter the salvage pathway and are enzymatically converted to NAD+ within cells. NMN is one step closer to NAD+ in the biosynthetic pathway, requiring only the enzyme NMNAT for conversion, while NR must first be phosphorylated by nicotinamide riboside kinases (NRKs) to form NMN.
Both precursors have been extensively used in animal studies, where they have been shown to elevate tissue NAD+ levels and activate downstream sirtuin pathways. However, the pharmacokinetics, tissue distribution, and dose-response relationships of these precursors differ — variables that researchers must carefully consider when designing experiments.
Direct NAD+ in Research
Direct NAD+ is also used in laboratory research, particularly in cell culture and in vitro enzymatic assays where precise control over NAD+ concentrations is required. In cell-free systems, direct NAD+ allows researchers to study sirtuin kinetics, PARP activity, and other NAD+-dependent reactions without the confounding variable of biosynthetic conversion.
The choice between precursors and direct NAD+ depends on the experimental question. For in vivo studies exploring systemic NAD+ metabolism, precursors are often preferred due to their bioavailability profiles. For mechanistic in vitro work, direct NAD+ provides the precision needed to dissect enzyme kinetics and pathway dynamics.
The NAD+ Metabolome: Salvage and De Novo Synthesis
NAD+ is not simply consumed and discarded — it is recycled through elegant biosynthetic pathways that the cell tightly regulates.
The Salvage Pathway
The salvage pathway is the dominant route for maintaining NAD+ levels in most mammalian cell types. When NAD+ is consumed by sirtuins, PARPs, or CD38, it releases nicotinamide (NAM) as a byproduct. The enzyme nicotinamide phosphoribosyltransferase (NAMPT) — often described as the rate-limiting enzyme in NAD+ salvage — converts NAM to NMN. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).
NAMPT expression and activity have themselves become subjects of intense research. NAMPT levels fluctuate with circadian rhythm and decline with age in several tissue types in animal models, potentially contributing to the age-related drop in NAD+.
De Novo Synthesis
NAD+ can also be synthesised de novo from the amino acid tryptophan via the kynurenine pathway. This route is particularly important in liver and kidney tissue. The de novo pathway involves multiple enzymatic steps and is regulated at several points, most notably at indoleamine 2,3-dioxygenase (IDO) and quinolinate phosphoribosyltransferase (QPRT).
Understanding the relative contributions of salvage versus de novo synthesis in different tissues and under different experimental conditions is an ongoing area of research, with implications for how NAD+ depletion is best addressed in various model systems.
Current State of Research and Future Directions
NAD+ research is entering what many scientists consider a golden era. Several key questions are driving the field forward:
The breadth of NAD+’s involvement in cellular biology means that advances in NAD+ research are likely to ripple outward across many fields, from basic cell biology to models of age-related decline, metabolic dysfunction, and neurodegeneration.
Handling and Storage Notes for Researchers
NAD+ is a relatively fragile molecule that requires careful handling in the laboratory:
Researchers should consult the certificate of analysis provided with their specific product for purity data and any batch-specific storage recommendations.
Conclusion
From its accidental discovery in a yeast fermentation experiment in 1906 to its current position at the cutting edge of ageing and metabolic research, NAD+ has proven to be one of the most consequential molecules in biochemistry. Its dual roles as a metabolic cofactor and a consumed signalling substrate give it a unique position in cellular biology — one that researchers are still working to fully understand.
As analytical tools improve and our understanding of NAD+ compartmentalisation, tissue-specific dynamics, and cross-pathway interactions deepens, this century-old molecule continues to open new doors for scientific investigation. For researchers working in metabolism, ageing biology, DNA repair, and beyond, NAD+ remains an indispensable subject of study — and a remarkably productive one.
This material is provided by Trusted Peptides for informational and research purposes only. NAD+ products supplied by Trusted Peptides are intended solely for in vitro and in vivo laboratory research. They are not intended for human consumption, therapeutic use, or diagnostic purposes. Researchers are responsible for ensuring compliance with all applicable regulations and institutional guidelines.